Gefapixant
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. It acts as an antagonist of the P2RX3 receptor.
It was authorized for medical use in the European Union in September 2023.
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. It acts as an antagonist of the P2RX3 receptor.
It was authorized for medical use in the European Union in September 2023.